Alkem Laboratories launched Renocia Exo on September 8, 2026. The product is India’s first patented Ginsenoside Exosome-based hair growth serum designed to support follicular health.

The launch addresses rising dermatological concerns regarding hair loss among both ageing adults and younger individuals. The company positioned the therapy as a response to genetic, lifestyle, and environmental stressors driving progressive thinning.

Product Formulation

Renocia Exo integrates multiple regenerative technologies into a single daily therapy. The formulation combines Ginsenoside phyto-exosomes, biomimetic peptides, copper peptides, and stem cell-supportive actives.

Unlike conventional topicals that focus solely on visible growth, the serum targets interconnected biological processes. It aims to support follicular vitality, scalp health, and the natural hair growth cycle by addressing oxidative stress, inflammation, and cellular signalling changes.

Market Context

Sandep Singh, Managing Director of Alkem, noted that the science of hair restoration has evolved significantly over the last decade. He highlighted that hair loss is driven by a complex interplay of mechanisms including follicular miniaturization and altered microenvironments.

The product is free from alcohol, sulphates, silicones, parabens, and mineral oil. It is intended for regular use as part of dermatologist-guided management.

Portfolio Expansion

With this launch, Alkem strengthens its dermatology portfolio. The company leverages its 53-year legacy and presence in chronic therapies to translate emerging scientific insights into therapeutic innovations.

Alkem operates 20 manufacturing facilities and R&D centres across India and the US. It maintains a dominant position in anti-infectives, gastrointestinal, and pain management drugs while expanding in dermatology and urology.

Alkem Laboratories shareholders approved all six resolutions proposed at the company's 52nd Annual General Meeting (AGM) held on August 27, 2026. The meeting was conducted through video conferencing and other audio-visual means, with Executive Chairman Basudeo N. Singh presiding over the proceedings.

The company provided remote e-voting facilities from August 24 to August 26, 2026, followed by e-voting during the AGM for attending members. A total of 77 members attended the virtual meeting, representing both promoter and public shareholding categories.

Key Resolutions Approved

Shareholders approved the adoption of audited standalone and consolidated financial statements for FY26. The meeting also confirmed the payment of interim dividend and declared a final dividend on equity shares for the financial year ended March 31, 2026.

Board appointments received shareholder approval:

• Sandeep Singh, Managing Director, was re-appointed after retiring by rotation
• Sarvesh Singh was re-appointed following retirement by rotation
• Madhurima Singh was re-appointed as Executive Director for five years, from December 20, 2026, to December 19, 2031

The company also ratified remuneration for Suresh D. Shenoy as Cost Auditor for FY26.

Voting Results

What the Numbers Show

Promoter group participation remained consistent across most resolutions, with approximately 99.09% of promoter-held shares voting in favour of financial statement adoption and dividend declaration. However, promoter voting participation dropped to 77.38% for Madhurima Singh's re-appointment, where promoters are classified as interested parties under SEBI LODR regulations.

Public institutional investors showed varying approval rates for director appointments. Sandeep Singh's re-appointment received 81.89% support from public institutions, while Sarvesh Singh secured 94.95% backing from the same category. These divergences suggest differentiated shareholder perspectives on individual director tenures despite overall resolution passage.